CLAIMS

1. A method of producing a biological product using a rhabdovirus-free Sf9 or Sf21 insect cell, or a rhabdovirus-free cell passaged therefrom, wherein the method comprises the steps of:

a) providing the rhabdovirus-free Sf9 or Sf21 insect cell, or the rhabdovirus-free cell passaged therefrom; and

b) producing the biological product in said rhabdovirus-free cell.

2. The method of claim 1, wherein the insect cell is an Sf9 cell.

3. The method of claim 2, wherein the Sf9 cell is derived from the cell line deposited as ATCC CRL-1711.

4. The method of claim 1, wherein the insect cell is an Sf21 cell.

5. The method of claim 1, wherein the biological product is for therapeutic or diagnostic purposes.

6. The method of claim 1, wherein the biological product is a protein, peptide, drug substance, virus-like particle (VLP), antibody, growth factor, polysaccharide, nucleic acid, virus, or vaccine antigen.

7. The method of claim 1, wherein the biological product is DNA.

8. The method of claim 1, wherein the biological product is RNA.

9. The method of claim 1, wherein the biological product is a recombinant virus for gene therapy.

10. The method of claim 1, wherein the biological product is a therapeutic protein or an enzyme.

11. The method of claim 1, wherein the biological product is a Calicivirus VLP.

12. The method of claim 1, wherein the biological product is a Norovirus VLP.

13. The method of claim 1, wherein the biological product is a protein and the protein is glycosylated.

14. The method of claim 1, wherein the insect cell is free of a nucleotide sequence having at least 70% homology to SEQ ID NO:1.

15. The method of claim 1, wherein the insect cell is free of a nucleotide sequence comprising the sequence according to SEQ ID NO:1.

16. The method of claim 1, wherein the biological product is a protein.

17. The method of claim 1, wherein the biological product is a peptide.

18. The method of claim 1, wherein the biological product is a drug substance.

19. The method of claim 1, wherein the biological product is a virus-like particle (VLP).

20. The method of claim 1, wherein the biological product is an antibody.

21. The method of claim 1, wherein the biological product is a growth factor.

22. The method of claim 1, wherein the biological product is a polysaccharide.

23. The method of claim 1, wherein the biological product is a nucleic acid.

24. The method of claim 1, wherein the biological product is a virus.

25. The method of claim 1, wherein the biological product is a vaccine antigen.

26. The method of claim 1, wherein the cell is comprised in a baculovirus-insect cell expression system.

27. The method of claim 1, wherein the cell is a rhabdovirus-free cell passaged from a rhabdovirus-free Sf9 or Sf21 insect cell.

28. The method of claim 1, wherein the cell is a rhabdovirus-free cell passaged from a rhabdovirus-free Sf9 cell, wherein the Sf9 cell is derived from the cell line deposited as ATCC CRL-1711.

29. A method of producing a biological product in an insect cell, the method comprising the steps of:

a) providing the insect cell,

b) confirming the absence of a rhabdovirus in the insect cell, and

c) producing the biological product in the insect cell,

wherein the rhabdovirus comprises a sequence having at least 95% homology to SEQ ID NO: 1.

30. A biologic approved for use in a human, substantially free of a virus having at least 70% homology to SEQ ID NO: 1, wherein the biologic is produced in an insect cell.

31. The biologic of claim 30, wherein the virus comprises a sequence according to SEQ ID NO: 1.

32. The biologic of claim 30 or 31, wherein the insect cell is an SF9 cell.

33. The biologic of claim 32, wherein the SF9 cell is derived from the cell line deposited as ATCC CRL-1711.

34. The biologic of claim 31 or 32, wherein the biologic is a vaccine or a virus-like particle preparation.